Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma

doi:10.19439/j.sjos.2022.04.012

Abstract

Abstract: PURPOSE: To investigate the effect of propranolol on urine bFGF, MMP-2, MMP-9 expression of children with proliferative infantile hemangioma(IH), so as to clarify the mechanism of propranolol in treating IH. METHODS: From June 2018 to June 2019, thirty-four children with proliferative IH were treated with oral propranolol. In addition, twenty-one normal children (age <12 months) were chosen as the control group. 10 mL of sterile morning urine were collected before and 2 months after oral administration of propranolol in infants with IH. All blood samples were placed in ordinary disinfection test tubes, centrifuged at 1 000 r/min for 10 min, the supernatant of urine was collected and stored separately. The urine samples of normal control group were processed in the same way. The expression levels of bFGF in the urine of children with proliferative IH before and 2 months after oral administration of propranolol and in the normal control group were detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of MMP-2 and MMP-9 in the urine of children with proliferative IH before and 2 months after treatment and in the control group were detected by gelatin zymography. SPSS 22.0 software package was used to analyze the data. RESULTS: Two months after oral propranolol treatment, the concentration of bFGF in urine was significantly lower than that before treatment (P<0.01), but still significantly higher than that in the control group (P<0.05). The expression levels of MMP-2 and MMP-9 were significantly lower than those before treatment(P<0.01), but still higher than those in the control group (P<0.05). CONCLUSIONS: One of the mechanisms of propranolol in the treatment of children with proliferative IH may be through inhibiting the expression levels of bFGF, MMP-2 and MMP-9, and then inhibiting the proliferation and angiogenesis of vascular endothelial cells in IH, so as to achieve the effect of treating hemangioma. The detection of the expression levels of bFGF, MMP-2 and MMP-9 in urine can be used as the index for oral propranolol treatment of children with proliferative IH.

Key words: Propranolol, Infantile hemangioma, Proliferative phase, Urine, Basic fibroblast growth factor, Matrix metalloproteinase 2, Matrix metalloproteinase 9

CLC Number:

R739.8

YUAN Wei-li, WANG Xu-kai. Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma[J]. Shanghai Journal of Stomatology, 2022, 31(4): 400-405.

References

[1] Haggstrom AN, Drolet BA, Baselga E, et al.Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics[J]. J Pediatr, 2007, 150(3): 291-294.
[2] Haggstrom AN, Lammer EJ, Schneider RA, et al.Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development[J]. Pediatrics, 2006, 117(3): 698-703.
[3] 郑家伟, 张凌, 陈正岗. 婴幼儿血管瘤的诊断与治疗[J]. 中国口腔颌面外科杂志, 2015, 13(4): 289-296.
[4] 郑家伟, 张凌. 婴幼儿血管瘤治疗理念与方法的转变[J].中华口腔医学研究杂志(电子版), 2015, 9(2): 91-94.
[5] Satterfield KR, Chambers CB.Current treatment and management of infantile hemangiomas[J]. Surv Ophthalmol, 2019, 64(5): 608-618.
[6] Soliman YS, Khachemoune A.Infantile hemangiomas: our current understanding and treatment options[J]. Dermatol Online J, 2018, 24(9): 1-14.
[7] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[8] 刘学健, 秦中平, 邰茂众, 等. 普萘洛尔治疗婴幼儿腮腺血管瘤的临床观察[J]. 中华口腔医学杂志, 2010, 45(5): 292-294.
[9] Prey S, Voisard JJ, Delarue A, et al.Safety of propranolol therapy for severe infantile hemangioma[J]. JAMA, 2016, 315(4): 413-415.
[10] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[11] Chang J, Most D, Bresnick S, et al.Proliferative haemangiomas: analysis of cytokine gene expression and angiogenesis[J]. Plast Reconstr Surg, 1999, 103(1): 1-9.
[12] Folkman J.Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis[J]. N Engl J Med, 1995, 333(26): 1757-1763.
[13] 张莉, 陈乾, 李丹, 等. 血VEGF和尿bFGF在血管性疾病鉴别诊断中的应用价值[J]. 中华医学杂志, 2011, 91(16): 1092-1095.
[14] Yang XJ, Jiang YH, Zheng JW, et al.The role of serum basic fibroblast growth factor, estradiol and urine basic fibroblast growth factor in differentiating infantile haemangiomas from vascular malformations[J]. Phlebology, 2011, 26(5): 191-196.
[15] Zhong S, Yang G, Xia C, et al.Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma[J]. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(5): 614-619.
[16] 李琳, 王胜春, 于建斌.MMP 9、VEGF在婴幼儿血管瘤中的表达及意义[J]. 中国实用医药, 2015, 10(12): 66-67.
[17] Marler JJ, Fishman SJ, Kilroy SM, et al.Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies[J]. Pediatrics, 2005, 116(1): 38-45.
[18] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck[M]. New York: Wiley-Liss Inc., 1999:3, 57-58, 93-169.
[19] Tan ST, Itinteang T, Leadbitter P.Low-dose propranolol for infantile haemangioma[J]. J Plast Reconstr Aesthet Surg, 2011, 64(3): 292-299.
[20] 胡强, 王琦, 商爱农, 等. 皮肤血管瘤中MC与bFGF关系的实验研究[J]. 中华整形外科杂志, 2004, 20(1): 69-71.
[21] 董长宪, 李恭才. 碱性纤维母细胞生长因子在血管瘤及血管畸形中的表达[J]. 中华小儿外科杂志, 1997, 18(6): 322-324.
[22] Visse R, Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry[J]. Circ Res, 2003, 92(8): 827-839.
[23] Annabi B, Lachambre MP, Plouffe K, et al.Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion[J]. Pharmacol Res, 2009, 60(5): 438-445.
[24] Jadhav U, Chigurupati S, Lakka SS, et al.Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells[J]. Int J Oncol, 2004, 25(5): 1407-1414.
[25] Storch CH, Hoeger PH.Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269-274.
[26] Mitropoulos D, Kyroudi-Voulgari A, Stratigea F, et al.Beta-adrenergic receptor blockade and prostate peptide growth factor expression in the rat[J]. Immunopharmacol Immunotoxicol, 2010, 32(1): 105-109.
[27] Kozawa O, Niwa M, Matsuno H, et al.Stimulatory effect of basic fibroblast growth factor on induction of heat shock protein 27 in osteoblasts: role of protein kinase C[J]. Arch Biochem Biophys, 2001, 388(2): 237-242.
[28] Thaker PH, Han LY, Kamat AA, et al.Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma[J]. Nat Med, 2006, 12(8): 939-944.
[29] Yang EV, Sood AK, Chen M, et al.Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells[J]. Cancer Res, 2006, 66(21): 10357-10364.
[30] Sood AK, Bhatty R, Kamat AA, et al.Stress hormone-mediated invasion of ovarian cancer cells[J]. Clin Cancer Res, 2006, 12(2): 369-375.